Parkview Laboratory: Test Directory
Home
Test Directory
About Us
Mission & Vision Statements
Medical Directors and Technical Consultants
Administrators
Certification and Accreditation Information
Laboratory Locations
Patient Information
Where can I get my blood drawn?
Pay your Bill, Get a Price Estimate, Is Parkview In Network
My Chart - Get Access / Get Lab Results
On My Way
Patient Collection Instructional Sheets
What is Direct Access Testing and is it right for you
Lab Links
Parkview Health
External Lab Resource
PHL Clients
MEDICARE NUMBER AND CARD CHANGES
Inappropriate Duplicate Testing
Flow Cytometry Ordering Guidelines
Certification and Accreditation Information
Cytology Collection Information
Histology Collection Information
Specimen Collection and Handling Requirements
Microbiology Specimen Collection, Rejection and Safety Information
Specimen Types, Descriptions, and Definitions
Billing (Insurance/Account/Patient/Medicare) Definitions and Information
Customer Service
How to use this Online Directory
Physicians Quick Reference for Medicare Preventive Services
View Medical Necessity Guide
View Stat Eligible Testing Report
HIV-1 Integrase Genotype
Last Modified:
5/2/2022 1:59:49 PM
Medical Necessity Documentation:
Client Notes:
Patient Preparation:
Specimen Requirements:
2.0 mL FROZEN Plasma from a
Lavender Top Tube
- EDTA in a Plastic Vial
Collection Instructions:
Value of last viral load and date of last viral load must be provided with the order
Separate plasma from the cells by centrifugation within 24 hours after collection.
Minimum Volume:
0.6 mL Plasma
Transport & Storage: Temperature/Stability:
24 hours Ambient
5 days Refrigerated
35 days Frozen (Preferred)
Ship frozen.
Rejection Criteria:
Gross hemolysis • Lipemia • Serum • Non-centrifuged PPT • Frozen PPT (in situ) • Heparinized plasma
Reference Range:
Refer to Interpretive Results
Critical Ranges:
Test Comments:
Methodology:
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) • Sequencing
Clinical Significance:
The emergence of integrase drug resistance mutations has been observed in vitro and in patients experiencing virologic failure on raltegravir in clinical trials. Twenty three percent of patients receiving raltegravir in a clinical trial experienced virologic failure at 48 weeks and genotypic analysis detected raltegravir associated resistance mutations in 68% of virologic failures. This assay amplifies and sequences the HIV-1 integrase gene and reports mutations at positions associated with integrase inhibitor drug resistance.
Documentation:
Custom Panel:
No
PRODUCTION SCHEDULE
Turn Around Time:
5 to 8 days
Days Performed:
Monday, Friday
Sites Performed:
Quest - Chantilly to San Juan Capistrano
PHL Test Code:
HIVI
EPIC Test Code:
IMO1957
Send Out Test Code:
16868
Alternate Test Names:
Elvitegravir; HIV Integrase Genotype; HIV-1 Integrase Mutations; HIV-1 Integrase Strand Transfer Inhibitor; Isentress (Raltegravir, MK-0518) Resistance; MK-0518; Raltegravir
Included Tests:
CPT Coding:
87906
Go back to the top of the page.